Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Rizzo

Showing results (51-60 of 381) with videos related to

Pageof 39
Sort By:
JAMA Oncology|March 3, 2022
Cabozantinib for Treatment of Brain Metastases in Patients With Renal Cell CarcinomaAlessandro Rizzo, Veronica Mollica, Francesco Massari
Immunotherapy|April 6, 2023
The evolution of biliary tract cancer: introducing a special focus issue from <i>Immunotherapy</i>Lauren Coyle, Alessandro Rizzo, Dalia Ricci
Physical Review Letters|December 8, 2016
Continuous-Time Discrete-Distribution Theory for Activity-Driven NetworksLorenzo Zino, Alessandro Rizzo, Maurizio Porfiri
European Urology Oncology|November 18, 2020
Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485Alessandro Rizzo, Veronica Mollica, Francesco Massari
Expert Review of Gastroenterology & Hepatology|February 28, 2022
Second-line fluoropyrimidine-based doublet chemotherapy for advanced biliary tract cancer: a new standard of care?Alessandro Rizzo, Antonio Cusmai, Gennaro Palmiotti
European Urology|July 7, 2020
Re: Hanbing Song, Bobak Seddighzadeh, Matthew R. Cooperberg, Franklin W. Huang. Expression of ACE2 and TMPRSS2, the SARS-CoV-2 Receptor and Co-Receptor, in Prostate Epithelial Cells. Eur Urol. In press DOI: 10.1016/j.eururo.2020.04.065Alessandro Rizzo, Veronica Mollica, Francesco Massari
European Urology Oncology|September 18, 2021
Re: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(21)00152-2: The Conflict of Adding Immunotherapy to Chemotherapy in Metastatic Urothelial Carcinoma: A Matter of the Right Timing?Veronica Mollica, Alessandro Rizzo, Francesco Massari
European Urology Oncology|June 20, 2020
Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?Veronica Mollica, Alessandro Rizzo, Francesco Massari
International Journal of Molecular Sciences|October 26, 2024
Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and ChallengesAlessandro Rizzo, Oronzo Brunetti, Giovanni Brandi
The Lancet. Oncology|June 4, 2021
Adjuvant immunotherapy in muscle-invasive urothelial carcinomaAlessandro Rizzo, Veronica Mollica, Francesco Massari
Pageof 39

Showing results (51-60 of 381) with videos related to

Sort By:
Pageof 39
JAMA Oncology|March 3, 2022
Cabozantinib for Treatment of Brain Metastases in Patients With Renal Cell CarcinomaAlessandro Rizzo, Veronica Mollica, Francesco Massari
Immunotherapy|April 6, 2023
The evolution of biliary tract cancer: introducing a special focus issue from <i>Immunotherapy</i>Lauren Coyle, Alessandro Rizzo, Dalia Ricci
Physical Review Letters|December 8, 2016
Continuous-Time Discrete-Distribution Theory for Activity-Driven NetworksLorenzo Zino, Alessandro Rizzo, Maurizio Porfiri
European Urology Oncology|November 18, 2020
Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485Alessandro Rizzo, Veronica Mollica, Francesco Massari
Expert Review of Gastroenterology & Hepatology|February 28, 2022
Second-line fluoropyrimidine-based doublet chemotherapy for advanced biliary tract cancer: a new standard of care?Alessandro Rizzo, Antonio Cusmai, Gennaro Palmiotti
European Urology|July 7, 2020
Re: Hanbing Song, Bobak Seddighzadeh, Matthew R. Cooperberg, Franklin W. Huang. Expression of ACE2 and TMPRSS2, the SARS-CoV-2 Receptor and Co-Receptor, in Prostate Epithelial Cells. Eur Urol. In press DOI: 10.1016/j.eururo.2020.04.065Alessandro Rizzo, Veronica Mollica, Francesco Massari
European Urology Oncology|September 18, 2021
Re: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(21)00152-2: The Conflict of Adding Immunotherapy to Chemotherapy in Metastatic Urothelial Carcinoma: A Matter of the Right Timing?Veronica Mollica, Alessandro Rizzo, Francesco Massari
European Urology Oncology|June 20, 2020
Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?Veronica Mollica, Alessandro Rizzo, Francesco Massari
International Journal of Molecular Sciences|October 26, 2024
Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and ChallengesAlessandro Rizzo, Oronzo Brunetti, Giovanni Brandi
The Lancet. Oncology|June 4, 2021
Adjuvant immunotherapy in muscle-invasive urothelial carcinomaAlessandro Rizzo, Veronica Mollica, Francesco Massari
Pageof 39